← Back to Clinical Trials
Recruiting NCT06306586

NCT06306586 A Digital Treatment for Adolescents With Eating Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06306586
Status Recruiting
Phase
Sponsor Haukeland University Hospital
Condition Eating Disorders
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-03-11
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Digital Treatment for Adolescents With Eating Disorders

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-03-11 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this feasibility study is to evaluate the feasibility and preliminary clinical outcomes of a personalized digital treatment for adolescents with eating disorders. The main objectives are to: i) Evaluate whether a personalized digital treatment for adolescents with eating disorders are feasible in a child and adolescent psychiatric outpatient clinic. ii) Evaluate who benefits from a personalized digital treatment for adolescents with eating disorders (what works for whom?) iii) Evaluate the cost-benefit of a personalized digital treatment for adolescents with eating disorders. Participants will be enrolled in a 10-week digital treatment including weekly therapist contact. They will be asked to complete self-report questionnaires at pre-, during, post- and 3- and 6-months follow-up.

Eligibility Criteria

Inclusion Criteria: A. Diagnosed with F50.1 Atypical anorexia nervosa, F50.3 Atypical bulimia nervosa, F50.8 Other eating disorders, F50.9 Eating disorder, unspecified B. Age between 15 and 18 years. C. Stable dose of medication for a co-morbid psychiatric treatment for six weeks and who continue to meet study entry criteria. D. Internet access. E. Speaks and write Norwegian. Exclusion Criteria: A. Diagnosed with F50.0 Anorexia nervosa or F50.2 Bulimia nervosa B. Disorders of psychological development (F80-F89). C. Patients with avoidant restrictive food intake disorders (F50.82) D. Participants with a co-morbid medical condition or disorder known to influence eating or weight (i.e., pregnancy, cancer), psychotic disorders, acute suicidality, or substance abuse and/or substance dependence and severe depressive episode. E. Receiving inpatient- or face to face psychological treatment.

Contact & Investigator

Central Contact

Emilie Nordby, MA

✉ emilie.sektnan.nordby@helse-bergen.no

📞 55975000

Principal Investigator

Tine Nordgreen, PhD

PRINCIPAL INVESTIGATOR

Division of Psychiatry, Haukeland University Hospital

Frequently Asked Questions

Who can join the NCT06306586 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 18 Years, studying Eating Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06306586 currently recruiting?

Yes, NCT06306586 is actively recruiting participants. Contact the research team at emilie.sektnan.nordby@helse-bergen.no for enrollment information.

Where is the NCT06306586 trial being conducted?

This trial is being conducted at Bømlo, Norway, Bergen, Norway, Haugesund, Norway.

Who is sponsoring the NCT06306586 clinical trial?

NCT06306586 is sponsored by Haukeland University Hospital. The principal investigator is Tine Nordgreen, PhD at Division of Psychiatry, Haukeland University Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology